Related Experiment Video

Updated: Jul 13, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Molecularly targeted oncology therapeutics and prolongation of the QT interval

Elizabeth L Strevel1, Douglas J Ing, Lillian L Siu

  • 1Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 1, 2007
PubMed

Insights

Molecularly targeted cancer therapies can cause QT interval prolongation, a cardiac risk. This review covers its mechanisms, assessment, and management in oncology drug development.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Novel molecularly targeted agents in cancer therapy present unique adverse effects compared to conventional chemotherapy.
  • QT interval prolongation, a cardiac toxicity linked to fatal arrhythmias, is a recognized risk with several new oncology drugs.
  • Existing guidelines for monitoring drug-induced QT prolongation were not specifically developed for cancer patients.

Purpose of the Study:

  • To review the pathophysiology and preclinical assessment of QT prolongation.
  • To summarize molecularly targeted agents associated with QT effects.
  • To explore strategies for managing this cardiac toxicity during oncology drug development.

Main Methods:

  • Literature review of molecularly targeted agents and their associated QT prolongation.
  • Analysis of preclinical QT assessment methodologies.
  • Examination of current guidelines for QT evaluation in early-phase clinical trials.

Main Results:

  • Several classes of molecularly targeted agents, including HDAC inhibitors and TKIs, are associated with QT prolongation.
  • Preclinical assessment methods and evolving regulatory guidelines for QT evaluation are discussed.
  • The unique considerations for QT prolongation in oncology patients are highlighted.

Conclusions:

  • Understanding and managing QT prolongation is crucial for the safe development of molecularly targeted cancer therapies.
  • Tailored approaches are needed to address cardiac toxicity in the oncology patient population.
  • Further research into mechanisms and mitigation strategies for QT prolongation is warranted.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...